잠시만 기다려 주세요. 로딩중입니다.

Nesfatin-1 Hormone Levels in Patients with Antisocial Personality Disorder and Their Relationship with Clinical Variables

Psychiatry Investigation 2020년 17권 9호 p.889 ~ 895
Kaya Suheda, Ozsoy Filiz, Tasci Gulay, Kalayci Mehmet,
소속 상세정보
 ( Kaya Suheda ) - Elazig Mental Health and Diseases Hospital
 ( Ozsoy Filiz ) - Tokat State Hospital Department of Psychiatry
 ( Tasci Gulay ) - Elazig Fethi Sekin City Hospital
 ( Kalayci Mehmet ) - Elazig Fethi Sekin City Hospital

Abstract


Objective: This study aims to investigate the levels of nesfatin-1-hormone in patients with Antisocial Personality Disorder (ASPD) and their relationship with clinical variables.

Methods: A total of 90 people (45 ASPD, 45 controls) were included in our study. Sociodemographic Data Form, Beck-Depression-Inventory (BDI), Beck-Anxiety-Inventory (BAI), Barratt Impulsivity Scale (BIS-11), Buss-Durkee-Hostility-Inventory (BDHI) were applied to all participants. Venous blood samples were taken from participants at the same time of the day when they were hungry.

Results: It was found that the BDI and BAI scores of the ASPD were higher than those of the controls (p<0.001, for both scales). The scores in BIS-11; motor and nonplanning-impulsivity subscales were higher than those of the controls (p<0.001, 0.036, respectively). The scores obtained by the ASPD were higher in all subscales of BDHI (p<0.001). For the nesfatin-1-hormone, the values of the ASPD were lower than those of the controls (p=0.044). No relationship was found between the nesfatin-1-hormone and any other laboratory parameters and applied scales (p>0.05).

Conclusion: This is the first study to examine the nesfatin-1-hormone levels in patients with any personality disorder. Further studies with more participants are needed in different types of personality disorders to understand the relationship between personality disorder and nesfatin-1-hormone levels.

키워드

Antisocial personality disorder; Nesfatin-1; Impulsivity; Aggression

원문 및 링크아웃 정보

 

등재저널 정보

SCI(E)
KCI
KoreaMed